Compare KRT & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRT | JANX |
|---|---|---|
| Founded | 2000 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Plastic Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2019 | 2021 |
| Metric | KRT | JANX |
|---|---|---|
| Price | $52.63 | $17.69 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 18 |
| Target Price | ★ $46.50 | $33.81 |
| AVG Volume (30 Days) | 133.5K | ★ 722.2K |
| Earning Date | 11-05-2026 | 11-17-2026 |
| Dividend Yield | ★ 3.54% | N/A |
| EPS Growth | ★ 4.70 | N/A |
| EPS | ★ 1.80 | N/A |
| Revenue | ★ $467,743,000.00 | $10,000,000.00 |
| Revenue This Year | $12.22 | $194.24 |
| Revenue Next Year | $8.47 | N/A |
| P/E Ratio | $29.72 | ★ N/A |
| Revenue Growth | ★ 10.67 | N/A |
| 52 Week Low | $20.61 | $12.12 |
| 52 Week High | $56.06 | $35.34 |
| Indicator | KRT | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 49.90 | 54.90 |
| Support Level | $52.21 | $15.90 |
| Resistance Level | $55.36 | $19.16 |
| Average True Range (ATR) | 1.46 | 0.76 |
| MACD | -0.29 | 0.08 |
| Stochastic Oscillator | 17.95 | 65.11 |
Karat Packaging Inc is a distributor and manufacturer of disposable foodservice products and related items, including containers, bags, tableware, cups, lids, cutlery, straws, specialty beverage ingredients, gloves, and janitorial supplies, available in plastic, paper, biopolymer-based, and other compostable forms. The Company focuses on environmentally friendly products and provides customized solutions including product development, design, printing, and logistics services. It serves customers through chains and distributors, retail, and e-commerce/online, and operates in the manufacturing and distribution of single-use food and beverage products, as well as specialty food and beverage products and restaurant and warehouse supplies.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.